Tech Company Financing Transactions
Oniria Therapeutics Funding Round
Oniria Therapeutics, based in Barcelona, secured $1.4 million in funding from Botin Foundation, Bstartup and Mind the Gap.
Transaction Overview
Company Name
Announced On
5/11/2023
Transaction Type
Venture Equity
Amount
$1,400,128
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to continue advancing development of ONR-001, a first-in-class drug for eliminating persistent tumour cells that remain after conventional treatment.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Adolf Marsillach, Number 6 Sótano 2, Local 6
Barcelona, 08035
ES
Barcelona, 08035
ES
Phone
Undisclosed
Website
Email Address
Overview
Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Esther Riambau
Chief Scientific Officer
Héctor Palmer
Co-Founder
Xavier Barril
Co-Founder
Carlos Galdeano
Co-Founder
Isabel Puig
Browse more venture capital transactions:
Prev: 5/11/2023: Everseen venture capital transaction
Next: 5/11/2023: AccelerComm venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs